Tarsus Pharmaceuticals Third Quarter 2024 Earnings Beats Expectations
| 04685A2Y6 | 79.28 5.89 6.92% |
About 61% of 04685A2Y6's investor base is looking to short. The analysis of the overall prospects from investing in ATH 2673 07 JUN 31 suggests that many traders are, at the present time, alarmed. The current market sentiment, together with 04685A2Y6's historical and current headlines, can help investors time the market. In addition, many technical investors use ATH 2673 07 bond news signals to limit their universe of possible portfolio assets.
04685A2Y6 |
Tarsus Pharmaceuticals Third Quarter 2024 Results Key Financial Results Revenue US48.1m up by...
Read at simplywall.st
 |
ATH 2673 07 Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with 04685A2Y6 bond to make a market-neutral strategy. Peer analysis of 04685A2Y6 could also be used in its relative valuation, which is a method of valuing 04685A2Y6 by comparing valuation metrics with similar companies.
Peers
04685A2Y6 Related Equities
| BCDA | Biocardia | 7.07 | ||||
| NTGR | NETGEAR | 4.83 | ||||
| ARDX | Ardelyx | 2.77 | ||||
| MSN | Emerson Radio | 2.38 | ||||
| TARS | Tarsus Pharmaceuticals | 1.75 | ||||
| APGE | Apogee Therapeutics, | 1.47 | ||||
| SMMT | Summit Therapeutics | 2.88 | ||||
| EVTZF | Evertz Technologies | 3.43 |
Other Information on Investing in 04685A2Y6 Bond
04685A2Y6 financial ratios help investors to determine whether 04685A2Y6 Bond is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in 04685A2Y6 with respect to the benefits of owning 04685A2Y6 security.